injectable glp 1 agonist GLP-1 Agonists for Weight Loss: Safe or Risky? Could GLP-1 receptor agonists represent

Williams DM, Nawaz A, Evans M

Nevertheless, future studies should further collect real-world data outcomes or conduct rigorous clinical trials to thoroughly investigate the relationship between GLP-1 RAs and mood disorders

Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and a nested case-control study (Bezin et al., 2023) that reported increased risk for thyroid cancer following GLP-1 RA-based interventions

In one study , 1,961 adults with obesity or overweight plus at least one weight-related medical condition regained two-thirds of the weight they had lost within one year of stopping semaglutide treatment and lifestyle interventions

In head-to-head clinical trials, the tirzepatide group often showed greater weight reduction and better blood sugar control compared to the semaglutide group at the doses studied